Deniz Tural, Professor of Medical Oncology at the prestigious Koç University Hospital in Istanbul, shared on X:
“JNJ-6143 phase 1 results are impressive.
In heavily pretreated patients (median 6 prior therapies), confirmed PSA50/PSA90 rates were 71%/41%.
No AE-related dose reductions or discontinuations; 14 patients remain on treatment after a median 7.1-month follow-up.
PSA50 responses were also seen across high-risk subgroups, including AR-V7 and TP53/PTEN/RB1 alterations.
If confirmed in phase 3 and earlier-line studies, JNJ-6143 could become a strong contender in mCRPC.”
You can also read:
PROMPT Trial at ESMO 2026: Plasma ctDNA for HRR and PI3K/AKT Genotyping in mCRPC
